ASX - Delayed Quote AUD

Imricor Medical Systems, Inc. (IMR.AX)

1.4000

-0.0700

(-4.76%)

At close: 4:10:19 PM GMT+10

Imricor Medical Systems Reports Full Year 2024 Earnings

Imricor Medical Systems ( ASX:IMR ) Full Year 2024 Results Key Financial Results Net loss: US$29.7m (loss widened by...

Simply Wall St. last month

IMR.AX
-4.76%
When Will Imricor Medical Systems, Inc. (ASX:IMR) Breakeven?

We feel now is a pretty good time to analyse Imricor Medical Systems, Inc.'s ( ASX:IMR ) business as it appears the...

Simply Wall St. last month

IMR.AX
-4.76%
Imricor’s VISABL-AFL Trial for US FDA Approval Commences at Cardiovascular Institute of South Paris

MINNEAPOLIS, June 25, 2024--Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in real-time iCMR cardiac ablation products, is pleased to announce that the Vision-MR Ablation Catheter 2.0 for Treatment of Type I Atrial Flutter (VISABL-AFL) IDE clinical trial, commenced with two procedures performed at the Cardiovascular Institute of South Paris (ICPS) (https://icps.fr).

Business Wire 9 months ago

IMR.AX
-4.76%

Performance Overview

Return	IMR.AX	MSCI WORLD (^990100-USD-STRD)
YTD	+2.94%	-7.77%
1-Year	+169.23%	+4.19%
3-Year	+166.67%	+18.63%